SCHEMBL4185849

SCHEMBL4185849

Cc1ccc(Cl)cc1-c1[nH]c(-c2ccnc(N)n2)cc1C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 20/20 1.00
CDC7 O00311 2/20 0.77
PLK4 O00444 2/20 0.77
MAPK13 O15264 2/20 0.77
DAPK3 O43293 2/20 0.77
DYRK3 O43781 2/20 0.77
PRKD3 O94806 2/20 0.77
CHEK2 O96017 2/20 0.77
PRKCG P05129 2/20 0.77
CDK1 P06493 2/20 0.77
PRKACA P17612 2/20 0.77
CDK2 P24941 2/20 0.77
MARK3 P27448 2/20 0.77
MAPK1 P28482 2/20 0.77
FRK P42685 2/20 0.77
MAPK8 P45983 2/20 0.77
MAPK9 P45984 2/20 0.77
CSNK1A1 P48729 2/20 0.77
CSNK1D P48730 2/20 0.77
CDK8 P49336 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13731406 0.92 JAK2 (0.84) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL25008203 0.92 JAK2 (0.84) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL13731370 0.90 JAK2 (0.82) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL13732436 0.89 JAK2 (1.00) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL4183279 0.89 JAK2 (0.80) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL27946090 0.89 JAK2 (0.80) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL15755998 0.89 JAK2 (1.00) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL15755980 0.89 JAK2 (1.00) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL13731118 0.88 JAK2 (0.82) JAK2CDC7PLK4MAPK13DAPK3
SCHEMBL4179135 0.88 JAK2 (0.86) JAK2CDC7PLK4MAPK13DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9283224-B2 Substituted pyrimidinyl-pyrroles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-15 US claimed
US-20140155421-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-06-05 US claimed
EP-2699564-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2014-02-26 EP claimed
CN-103502241-A Substituted pyrimidinyl-pyrroles active as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2014-01-08 CN claimed
WO-2012143248-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-26 WO claimed
EP-2736514-B1 ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-10-18 EP disclosed
EP-2736514-B1 ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-10-18 EP disclosed
US-9670191-B2 Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-06 US disclosed
US-9670191-B2 Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-06 US disclosed
US-9670191-B2 Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-06 US disclosed
CN-103502241-B As the pyrimidinyl-pyrrolesactive active of the replacement of kinase inhibitor NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-23 CN disclosed
US-9283224-B2 Substituted pyrimidinyl-pyrroles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-15 US disclosed
WO-2012143248-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-26 WO disclosed
US-8263604-B2 Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-11 US disclosed
US-8263604-B2 Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-11 US disclosed
US-8263604-B2 Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-11 US disclosed
US-20090099221-A1 PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-04-16 US disclosed
US-20090099221-A1 PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-04-16 US disclosed
US-20090099221-A1 PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-04-16 US disclosed
WO-2007110344-A1 PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099221-A1 PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS CDK2, CDK1, CDK5 JAK2 18/4885CDC7 294/4885PLK4 194/4885
US-20140155421-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS JAK1, MAP3K1, MAP3K20 JAK2 11/4885CDC7 371/4885PLK4 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.